文献速递腹部技术与安全PETCTMR

FAP靶向PET显像在腹膜癌病中的应用

FAP-targeted PET imaging in peritoneal carcinomatosis.
PubMed 文献 · Br J Radiol · 2026-01-01

腹膜癌病常被常规CT/MRI和18F-FDG PET/CT低估,尤其对小、扁平或低FDG摄取的种植灶。FAPI PET靶向肿瘤相关成纤维细胞,头对头研究和荟萃分析显示其在腹膜病灶中肿瘤摄取、靶本比和诊断敏感度均高于FDG PET/CT,并可提高影像学腹膜癌指数。现有证据多为单中心、高验前概率人群,需前瞻性试验验证其临床获益。

要点

  • FAPI PET/CT对腹膜癌病的诊断敏感度高于FDG PET/CT,可减少低估分期。
  • FAPI PET可提高影像学腹膜癌指数,影响细胞减灭术和腹腔/全身治疗的患者选择。
  • 注意良性纤维炎性或修复性病变可能导致FAPI假阳性。

核心结论

  • FAPI PET/CT在腹膜病灶中肿瘤摄取和靶本比更高,诊断敏感度优于FDG PET/CT,可提高影像学腹膜癌指数并影响临床决策。

研究设计与样本

  • 基于头对头研究和荟萃分析的综合证据,纳入研究多为单中心、腹膜癌病验前概率高的队列,参考标准异质。

关键影像表现/征象

  • FAPI PET靶向肿瘤相关成纤维细胞,在腹部通常提供高肿瘤-本底对比。
  • FAPI PET/CT在腹膜病灶中显示更高的肿瘤摄取和肿瘤-本底比值。

诊断标准与关键数值

  • FAPI PET/CT诊断腹膜病灶的敏感度高于FDG PET/CT,并可提高影像学腹膜癌指数。

临床应用与阅片要点

  • FAPI PET/CT可用于改善腹膜转移灶的 mapping,辅助细胞减灭术和腹腔/全身治疗的患者选择,降低分期不足风险。
  • 阅片时需警惕良性纤维炎性或修复性过程导致的FAPI假阳性。

局限性

  • 现有数据以单中心研究为主,队列腹膜癌病验前概率高,参考标准异质。
  • 存在良性纤维炎性或修复性病变所致假阳性的可能。
  • 尚需前瞻性试验、与CT/MRI(包括PET/MRI)的比较、实施研究和卫生经济学评价来确认获益。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

Peritoneal carcinomatosis remains a major determinant of prognosis and operability in abdominopelvic malignancies, yet conventional CT/MRI and Fluorine-18([18F])-FDG PET/CT frequently underestimate peritoneal disease extent, particularly for small, flat, or low-FDG-avid implants. Fibroblast activation protein inhibitor (FAPI) PET targets cancer-associated fibroblasts within the tumour stroma and typically provides high tumour-to-background contrast, particularly in the abdomen. Across head-to-head studies and meta-analyses, FAPI PET/CT consistently demonstrates higher tumour uptake and tumour-to-background ratios in peritoneal lesions and higher diagnostic sensitivity than FDG PET/CT, with a downstream increase in imaging-derived peritoneal cancer index that shows the extent of the peritoneal disease. Emerging evidence suggests that improved peritoneal metastases mapping can meaningfully influence clinical decision-making by refining patient selection for cytoreductive surgery and intraperitoneal/systemic therapies and by reducing the risk of understaging. Current limitations include a predominance of single-centre data in cohorts with a high pre-test probability of peritoneal disease, heterogeneous reference standards, and potential false positives from benign fibro-inflammatory or reparative processes. Ongoing prospective trials, further comparisons with CT/MRI (including PET/MRI), implementation studies, and health-economic evaluations will be essential to define optimal indications and confirm outcome-relevant benefit.

来源:Br J Radiol,查看原文。版权归原作者所有。

引用

  1. Arçay Öztürk A, Liberale G, Flamen P, et al. FAP-targeted PET imaging in peritoneal carcinomatosis. Br J Radiol. 2026. PMID: 42011156. doi:10.1093/bjr/tqag087

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。